Efficacy News and Research

RSS

The FDA expands collaboration with CN Bio to investigate lung-on-a-chip model for inhaled drug evaluation applications

CN Bio today announced the U.S. Food and Drug Administration (FDA) has extended their research collaboration, for a further three years.

From CN Bio 5 May 2021

Pfizer/BioNTech and Moderna vaccines induce T-cell immunity against SARS-CoV-2

Researchers in the United States have shown that the Pfizer/BioNTech and Moderna messenger RNA (mRNA) vaccines are effective at generating T-cell immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 May 2021

Emergency physicians use heparin alternative to treat vaccine-induced blood clot

A new case report, detailed in Annals of Emergency Medicine, is the first known case of a patient with VITT (vaccine-induced thrombotic thrombocytopenia) treated with a heparin alternative following the Centers for Disease Control and Prevention (CDC) guidance.

5 May 2021

Pan-COVID-19 vaccine protects mice against SARS-CoV-2 variants

Researchers in the United States have identified short peptide sequences in the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are immunogenic in a mouse model and may provide protection against viral variants.

5 May 2021

New vaccine candidate provides breakthrough in the fight against malaria

A malaria vaccine candidate tested on children in West Africa has shown an efficacy of around 77 per cent, say scientists, hailing it as a breakthrough in the fight against the disease.

4 May 2021

Stomach-specific protein plays a key role in the progression of obesity

Scientists believe a stomach-specific protein plays a major role in the progression of obesity, according to new research in Scientific Reports.

4 May 2021

UTA researchers investigate a new approach to better treat battlefield TBIs

The chair of the Bioengineering Department at The University of Texas at Arlington is investigating whether a combination of nanoparticles and light therapy can better treat traumatic brain injuries on the battlefield.

4 May 2021

Moderna COVID-19 vaccine makes it on WHO Emergency Use Listing

Moderna has announced Emergency Use Listing granted by the World Health Organization for its COVID-19 mRNA vaccine.

4 May 2021

Could in vitro glycoengineering help produce better SARS-CoV-2 spike candidates for vaccine research?

A vexing problem in the development of vaccines has been the need to achieve the right glycosylation profile for the viral antigens. A new study, recently released as a preprint on the bioRxiv* server, shows how a sequential cell-free approach produced complex N-glycans from simpler types, in a one-pot reaction.

4 May 2021

Monoclonal antibody neutralizes all SARS-CoV-2 variants of concern

Researchers in Canada and the United States have identified a monoclonal antibody that potently neutralizes variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the ongoing coronavirus disease 2019 (COVIdD-19) pandemic.

3 May 2021

Researchers demonstrate real-world effectiveness of Johnson & Johnson COVID-19 vaccine

Researchers in the United States and India have conducted a study demonstrating the real-world effectiveness of a single dose of Johnson & Johnson’s Ad26.COV2.S vaccine at preventing infection with severe acute respiratory syndrome coronavirus 2 – the agent that causes coronavirus disease 2019 (COVID-19).

3 May 2021

New study launched to more accurately diagnose early hepatocellular carcinoma

A first of its kind cohort study on patients at high risk of developing primary liver cancer also known as hepatocellular carcinoma (HCC), has been launched to diagnose HCC more accurately at an earlier stage and to predict an individual's likelihood of developing the cancer.

3 May 2021

Simple application of UVC light could make common disinfectants safer to use

Over 400 common disinfectants currently in use could be made safer for people and the environment and could better fight the COVID-19 virus with the simple application of UVC light, a new study from the University of Waterloo shows.

3 May 2021

Designing effective multidrug-resistant-TB treatments based on DNA sequencing

Globally, tuberculosis is the most common bacterial infectious disease leading to death. The pathogen causing tuberculosis, Mycobacterium tuberculosis, has a number of peculiarities. One is that it is growing very slowly.

3 May 2021

SARS-CoV-2 antibodies are detectable up to a year after infection, finds study

A team of scientists from the United States has recently investigated the robustness and durability of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in coronavirus disease 2019 (COVID-19) patients. Their findings reveal that COVID-19 patients exhibit a strong anti-SARS-CoV-2 antibody response for up to 1 year and that the robustness of antibody response depends on the patient’s age and disease severity.

3 May 2021

Hopeaphenol inhibits entry of SARS-CoV-2 variants of concern into cells

A new study, released as a preprint on the bioRxiv* server, reports promising results with the natural product hopeaphenol, which successfully prevented the entry of the virus into host cells.

3 May 2021

As schools spend millions on air purifiers, experts warn of overblown claims and harm to children

Last summer, Global Plasma Solutions wanted to test whether the company's air-purifying devices could kill covid-19 virus particles but could find only a lab using a chamber the size of a shoebox for its trials. In the company-funded study, the virus was blasted with 27,000 ions per cubic centimeter.

3 May 2021

Low-profile thoracic aortic endograft minimizes complications, increases patient pool

Preliminary results of a clinical trial, presented today at the AATS 101st Annual Meeting, showed that a new, low-profile thoracic aortic endograft is safe and effective in the treatment of descending thoracic aortic aneurysm or penetrating atherosclerotic ulcer (PAU) diseases.

3 May 2021

Study reveals new broadly neutralizing and protective antibody against coronaviruses

In the setting of potentially reduced vaccine efficacy against coronavirus disease (COVID-19) due to emerging viral variants, the deployment of effective treatments based on monoclonal antibodies may be an additional strategy to help control the pandemic. A new study by US researchers, currently available on the bioRxiv* preprint server, describes the action of a specific antibody known as DH1047.

3 May 2021

Researchers develop a nanoparticle-based formulation with anti-SARS-CoV-2 activity

A study recently published in the journal Matter has demonstrated the development and validation of a nanoparticle-based formulation, capable of completely inhibiting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection blocking the interaction between viral spike protein and host cell angiotensin-converting enzyme 2 (ACE2).

3 May 2021

Efficacy News and Research

The FDA expands collaboration with CN Bio to investigate lung-on-a-chip model for inhaled drug evaluation applications

Pfizer/BioNTech and Moderna vaccines induce T-cell immunity against SARS-CoV-2

Emergency physicians use heparin alternative to treat vaccine-induced blood clot

Pan-COVID-19 vaccine protects mice against SARS-CoV-2 variants

New vaccine candidate provides breakthrough in the fight against malaria

Stomach-specific protein plays a key role in the progression of obesity

UTA researchers investigate a new approach to better treat battlefield TBIs

Moderna COVID-19 vaccine makes it on WHO Emergency Use Listing

Could in vitro glycoengineering help produce better SARS-CoV-2 spike candidates for vaccine research?

Monoclonal antibody neutralizes all SARS-CoV-2 variants of concern

Researchers demonstrate real-world effectiveness of Johnson & Johnson COVID-19 vaccine

New study launched to more accurately diagnose early hepatocellular carcinoma

Simple application of UVC light could make common disinfectants safer to use

Designing effective multidrug-resistant-TB treatments based on DNA sequencing

SARS-CoV-2 antibodies are detectable up to a year after infection, finds study

Hopeaphenol inhibits entry of SARS-CoV-2 variants of concern into cells

As schools spend millions on air purifiers, experts warn of overblown claims and harm to children

Low-profile thoracic aortic endograft minimizes complications, increases patient pool

Study reveals new broadly neutralizing and protective antibody against coronaviruses

Researchers develop a nanoparticle-based formulation with anti-SARS-CoV-2 activity

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News